Symphony tCGM System of Echo Therapeutics, Inc. has been listed in one of Scientific American’s online articles titled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings" on March 31, 2010.
Echo Therapeutics is a developer of Prelude SkinPrep System meant for the purpose of transdermal drug delivery and Symphony tCGM System, which is a transdermal, wireless, non-invasive continuous glucose monitoring (tCGM) system.
The Chairman of the Board and CEO of Echo Therapeutics Patrick T. Mooney stated that the visibility of the Prelude SkinPrep System and Symphony tCGM System among scientific professionals increases after being featured in one of Scientific American articles. Incorporating their patented technology of skin permeation control feedback with a hand-held, wireless device, Prelude can be used for preparing the skin surface for the monitoring components and non-invasive biosensors of the company’s Symphony tCGM System. Patrick added that the company has had six positive pilot studies conducted in the area of glucose monitoring and the company’s next-generation skin preparation product incorporates considerable improvements to the prototype utilized in early studies.